ANRO net incomeQ2 2026-$27.64M
ANRO net income was -$27.64M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$17.71M a year earlier. For the full fiscal 2025 it was -$63.24M, compared with -$61.43M in fiscal 2024.
Alto Neuroscience Inc. (ANRO) financials
For the twelve months ended Jun 30, 2026, Alto Neuroscience Inc. reported -$84.24M of net income.
- Net income, TTM
- -$84.24M
- Free cash flow, TTM
- -$68.84M
- EPS, diluted, TTM
- -$2.43
- Cash
- $243.73M
- Total debt
- $16.19M
- Market cap
- $1.12B
FY2023FY2025
FY2023FY2025
ANRO revenue and earnings growth
ANRO EPSQ2 2026-$0.65
ANRO diluted EPS was -$0.65 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$2.19, compared with -$2.50 in fiscal 2024.
ANRO free cash flowQ2 2026-$19.76M
ANRO free cash flow was -$19.76M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$13.78M a year earlier. For the full fiscal 2025 it was -$51.79M, compared with -$49.50M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $45.62M | $47.00M | $30.29M |
| Selling, general and admin | $20.75M | $21.61M | $7.52M |
| Operating income | -$66.36M | -$68.61M | -$37.81M |
| Interest expense | $2.47M | $1.38M | $1.37M |
| Income tax | $0 | $0 | $0 |
| Net income | -$63.24M | -$61.43M | -$36.30M |
| EPS, basic | -$2.19 | -$2.50 | -$9.73 |
| EPS, diluted | -$2.19 | -$2.50 | -$9.73 |
| Diluted shares | 28.9M | 24.6M | 3.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $176.48M | $168.73M | $82.55M |
| Current assets | $177.72M | $169.34M | $85.39M |
| Total assets | $184.69M | $177.54M | $86.63M |
| Current liabilities | $11.32M | $10.01M | $5.61M |
| Short-term debt | $585.0K | $0 | $0 |
| Long-term debt | $16.17M | $10.25M | $9.86M |
| Total debt | $16.76M | $10.25M | $9.86M |
| Total liabilities | $33.55M | $26.08M | $16.82M |
| Shareholders' equity | $151.14M | $151.46M | -$71.67M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$51.77M | -$47.42M | -$33.45M |
| Capital expenditures | $24.0K | $2.08M | $470.0K |
| Free cash flow | -$51.79M | -$49.50M | -$33.92M |
| Investing cash flow | -$24.0K | -$2.08M | -$470.0K |
| Financing cash flow | $60.08M | $135.69M | $68.13M |
| Stock-based compensation | $8.11M | $7.63M | $2.89M |
| Depreciation and amortization | - | $502.0K | $373.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $22.11M | $20.29M | $12.00M | $10.53M | $13.12M | $9.97M | $10.80M | $13.06M | $13.18M | $9.95M | $9.64M | $7.97M |
| Selling, general and admin | $7.02M | $6.84M | $5.06M | $4.43M | $5.56M | $5.70M | $6.20M | $5.83M | $5.16M | $4.43M | $2.12M | $1.75M |
| Operating income | -$29.13M | -$27.14M | -$17.05M | -$14.95M | -$18.68M | -$15.68M | -$17.00M | -$18.89M | -$18.34M | -$14.39M | -$11.77M | -$9.72M |
| Interest expense | $491.0K | $545.0K | $575.0K | $650.0K | $646.0K | $598.0K | $333.0K | $349.0K | $347.0K | $346.0K | $356.0K | $363.0K |
| Income tax | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - |
| Net income | -$27.64M | -$26.24M | -$16.18M | -$14.18M | -$17.71M | -$15.17M | -$15.20M | -$16.78M | -$16.03M | -$13.42M | -$11.22M | -$9.14M |
| EPS, basic | -$0.65 | -$0.80 | -$0.46 | -$0.52 | -$0.65 | -$0.56 | - | -$0.62 | -$0.60 | -$0.76 | -$2.99 | -$2.44 |
| EPS, diluted | -$0.65 | -$0.80 | -$0.46 | -$0.52 | -$0.65 | -$0.56 | - | -$0.62 | -$0.60 | -$0.76 | -$2.99 | -$2.44 |
| Diluted shares | 42.8M | 32.9M | - | 27.1M | 27.1M | 27.0M | - | 27.0M | 26.9M | 17.6M | - | 3.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $243.73M | $263.76M | $176.48M | $137.82M | $148.09M | $161.25M | $168.73M | $182.20M | $193.62M | $205.90M | $82.55M | $51.29M |
| Current assets | $247.32M | $269.13M | $177.72M | $139.45M | $149.85M | $163.52M | $169.34M | $183.53M | $195.41M | $208.31M | $85.39M | - |
| Total assets | $254.07M | $276.26M | $184.69M | $147.01M | $157.88M | $171.91M | $177.54M | $191.61M | $197.36M | $209.92M | $86.63M | - |
| Current liabilities | $16.65M | $13.12M | $11.32M | $9.04M | $8.13M | $7.26M | $10.01M | $14.02M | $9.84M | $8.01M | $5.61M | - |
| Short-term debt | $3.77M | $2.14M | $585.0K | - | - | - | $0 | $3.53M | $2.32M | $1.15M | $0 | - |
| Long-term debt | $12.42M | $13.88M | $16.17M | $20.31M | $20.12M | $19.94M | $10.25M | $6.63M | $7.74M | $8.81M | $9.86M | - |
| Total debt | $16.19M | $16.02M | $16.76M | $20.31M | $20.12M | $19.94M | $10.25M | $10.16M | $10.06M | $9.96M | $9.86M | - |
| Total liabilities | $34.82M | $32.89M | $33.55M | $35.45M | $34.47M | $32.82M | $26.08M | $26.56M | $17.58M | $16.82M | $16.82M | - |
| Shareholders' equity | $219.25M | $243.37M | $151.14M | $111.56M | $123.41M | $139.10M | $151.46M | $165.05M | $179.78M | $193.10M | -$71.67M | -$61.10M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.76M | -$27.09M | -$11.52M | -$9.92M | -$13.78M | -$16.56M | -$13.02M | -$11.73M | -$11.69M | -$10.98M | -$11.52M | -$7.76M |
| Capital expenditures | $0 | $556.0K | $0 | $0 | $0 | $24.0K | $506.0K | $1.00M | $340.0K | $224.0K | $352.0K | $43.0K |
| Free cash flow | -$19.76M | -$27.65M | -$11.52M | -$9.92M | -$13.78M | -$16.58M | -$13.53M | -$12.73M | -$12.03M | -$11.21M | -$11.88M | -$7.81M |
| Investing cash flow | $0 | -$556.0K | $0 | $0 | $0 | -$24.0K | -$506.0K | -$1.00M | -$340.0K | -$224.0K | -$352.0K | -$43.0K |
| Financing cash flow | -$273.0K | $114.94M | $50.19M | $153.0K | $613.0K | $9.13M | $49.0K | $1.32M | -$234.0K | $134.56M | $43.13M | $49.0K |
| Stock-based compensation | $3.55M | $2.82M | $1.95M | $2.19M | $2.00M | $1.97M | $1.57M | $2.00M | $1.89M | $2.18M | $606.0K | $541.0K |
| Depreciation and amortization | - | - | - | - | $100.0K | $171.0K | $170.0K | $200.0K | $100.0K | $97.0K | $112.0K | $100.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 14.85 | 20.52 | 15.69 | 15.42 | 18.43 | 22.53 | 16.92 | 13.09 | 19.85 | 26.02 | 15.22 | - |
| Debt to equity | 0.07 | 0.07 | 0.11 | 0.18 | 0.16 | 0.14 | 0.07 | 0.06 | 0.06 | 0.05 | - | - |
Source: XBRL data Alto Neuroscience Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ANRO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ANRO | - | - | -$84.24M | - | $1.12B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
ANRO FAQ
6 questionsIs ANRO profitable?
No. Alto Neuroscience Inc. reported a net loss of $84.24M for the twelve months ended Jun 30, 2026.How much cash and debt does ANRO have?
Alto Neuroscience Inc. reported $243.73M in cash and cash equivalents and $16.19M of debt on its most recent balance sheet in SEC filings.What is ANRO free cash flow?
Alto Neuroscience Inc. generated -$68.84M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$68.28M less capital expenditures.What is ANRO earnings per share?
Diluted earnings per share were -$2.43 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ANRO last report financial results?
The latest statements here come from Alto Neuroscience Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this ANRO financial data come from?
Quantisnow builds these statements from the structured XBRL data Alto Neuroscience Inc. files with the SEC. It is provided for information only and is not investment advice.